Trial Profile
Planned registrational trial of ganetespib in women with metastatic triple-negative breast cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 06 Aug 2013
Price :
$35
*
At a glance
- Drugs Ganetespib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 06 Aug 2013 This trial is expected to start in 2014, according to a Synta Pharmaceuticals media release.
- 06 Aug 2013 New trial record